Home / Library / Homocysteine Support

Homocysteine Support

Key nutrients: 5-MTHF (methylfolate) · Methylcobalamin (B12) · P5P (active B6) · Betaine (TMG)

Recommended test

Fasting Plasma Homocysteine

Homocysteine is an amino acid byproduct that the body normally recycles using B-vitamin-dependent pathways. When those pathways slow down — from B12/folate deficiency, genetic variants like MTHFR, or general methylation strain — homocysteine builds up in the blood, which is why it's tested as a marker of methylation and cardiovascular risk. Elevated levels have implications across cardiovascular, immune, and neurological systems. From a cardiac standpoint specifically, homocysteine is directly toxic to the endothelial lining of blood vessels — it reduces nitric oxide availability through oxidative stress, impairing the vessel's ability to relax and dilate normally, an early step in the atherosclerosis process.

Interpret all results with a healthcare provider — an elevated result should prompt a look at B12 and folate status specifically, since correcting an underlying deficiency (rather than just supplementing broadly) is usually the more precise approach.

What it's made of & why

Methyl-Guard's core nutrients

5-MTHF (L-5-Methyltetrahydrofolate)

The active, already-converted form of folate — bypasses the MTHFR enzyme step that roughly 60% of adults have a reduced-function variant of
Directly donates a methyl group needed to convert homocysteine back to methionine

Methylcobalamin (Active B12)

Required cofactor for the same homocysteine-to-methionine recycling step as folate
The active form, rather than cyanocobalamin, which needs an extra conversion step in the body

P5P (Pyridoxal-5-Phosphate, active B6)

Supports a second, separate homocysteine-clearing pathway (converting it to cysteine/taurine instead of recycling it)

Betaine (TMG)

An alternate methyl donor that recycles homocysteine to methionine through a folate-independent backup pathway

Research noteA randomized, placebo-controlled trial using this same combination — methylfolate, P5P, and methylcobalamin, personalized to MTHFR/MTR/MTRR genetic variants — found a 30% reduction in homocysteine and a 7.5% reduction in LDL cholesterol over 6 months versus placebo (54 people, ages 40-75).

What the research says

Evidence by outcome

Outcome	Approx. evidence base	Typical finding
Lowering homocysteine itself	Consistent across many RCTs, including trials of thousands	Reliably effective — typically 20-30%+ reductions; largest in those with low B12 or high baseline levels
Cardiovascular events (large outcome trials)	WENBIT, ~3,090 people with existing heart disease	No significant reduction in mortality or cardiovascular events despite a 28% homocysteine drop
Cognitive decline (general older adults)	NEJM RCT, 276 people	No cognitive benefit despite lowering homocysteine
Brain atrophy (mild cognitive impairment, VITACOG)	RCT in adults with MCI	Slowed the rate of brain atrophy — a more promising signal in this specific population
Bone turnover markers	2-year RCT, 135 people	No effect despite meaningful homocysteine reduction

The honest summary: B-vitamin supplementation is a very reliable way to lower homocysteine as a lab number. Whether that translates into a meaningful clinical outcome is much less consistent — general population trials for cardiovascular events, cognition, and bone health have mostly come back neutral, while people who are genuinely B12/folate deficient, or who have an elevated baseline homocysteine tied to a specific condition (like MCI in the VITACOG trial), appear to be the group most likely to see a real benefit.

It's also worth noting how these trials were designed: homocysteine-lowering was tested in isolation, as the only intervention. In practice here, elevated homocysteine is rarely addressed on its own — it's considered alongside inflammation (hs-CRP) and cholesterol/triglycerides at the same time, since these markers tend to travel together and compound each other's risk. A neutral result from lowering homocysteine alone isn't a strong argument against addressing it as part of that broader picture.

Research summary chart

View PDF ↗

Dosages used in studies

What the research actually tested

Goal	Typical dose	Forms used	Duration
Practitioner-used starting dose (this site)	1 capsule/day, titrated up; starts higher only if homocysteine is well above 20	Methyl-Guard, standard formula	Ongoing, retest to guide titration
General homocysteine lowering (research range)	Folate 0.8–1 mg + B12 0.4–0.5 mg + B6 10–40 mg	Folic acid or 5-MTHF, cyanocobalamin or methylcobalamin	6 months–2 years
MTHFR-personalized approach (research range)	5-MTHF + methylcobalamin + P5P (doses individualized to genotype)	Active/methylated forms	6 months
Methyl-Guard full label dose (research range)	5-MTHF ~1.2 mg, B12 ~1.2 mg, B6 (P5P) ~20 mg, Betaine ~1.8 g	Methylated forms + betaine	Ongoing, per practitioner

Note: the full label dose is 3 capsules, up to 3x/day. In practice, dosing typically starts at 1 capsule and titrates up from there based on retested homocysteine, rather than starting at the full label amount.

Safety notes & high-dose risks

What to watch for

High-dose folate can mask a B12 deficiency — folate can correct the anemia symptoms of B12 deficiency while the underlying neurological damage continues progressing undetected. This is why B12 status should always be checked before high-dose folate supplementation. Worth noting: this risk is specifically tied to folic acid (the synthetic form used in food fortification and many standard supplements) — a randomized study comparing the two directly found that 5-MTHF, the methylated form used in Methyl-Guard, is unlikely to mask the hematologic indicators of B12 deficiency the way folic acid does. This lowers the risk with this specific product, but checking B12 status is still good practice.
B6 at high doses (well above what's in Methyl-Guard, but worth knowing) has been linked to peripheral neuropathy with prolonged very-high-dose use — the P5P form here is well below typical concern thresholds.
Methotrexate interaction: 5-MTHF is not recommended alongside methotrexate specifically used for cancer therapy, since it can interfere with the drug's mechanism. It appears safe alongside lower-dose methotrexate used for psoriasis or rheumatoid arthritis — confirm with the prescribing provider either way.
Pregnancy: consult a healthcare provider before use.

Additional notes

Worth knowing

Why methylated forms specifically: roughly 60% of adults carry a reduced-function MTHFR variant, which limits how well the body converts standard folic acid into its usable, active form — 5-MTHF and methylcobalamin skip that conversion step entirely.
This overlaps with mitochondrial support: methylation strain and elevated homocysteine often travel together with the same inflammatory and mitochondrial patterns addressed elsewhere in this library (CoQ10, PQQ, NAC) — they're frequently addressed together rather than in isolation.
Retesting: homocysteine roughly 8-12 weeks after starting supplementation is a reasonable check-in point.
More is not better: once homocysteine normalizes, continuing to increase the dose doesn't provide additional benefit.

Shop on Fullscript Shop on Prodrome

Educational information only — not medical advice. Lab testing and any supplementation decisions should be made with a qualified healthcare provider who knows your personal health history. Research findings vary by population, dose, form, and study quality.

Some links go to Fullscript, where I may earn a commission at no extra cost to you. I only recommend supplements I've either used myself or seen work in my clients' lab data. Results vary from person to person.